Inspra Approved For First-Line CHF; Pfizer Expects Most Use Will Be Add-On
Executive Summary
Pfizer's Inspra is expected to be primarily used as add-on therapy for congestive heart failure despite FDA approval of the selective aldosterone blocker for first-line use
You may also be interested in...
Pfizer Launches Inspra; Will Help Company Reach $54 Bil. In 2004
Pfizer is beginning its launch of the congestive heart failure therapy Inspra
Pfizer Launches Inspra; Will Help Company Reach $54 Bil. In 2004
Pfizer is beginning its launch of the congestive heart failure therapy Inspra
Pfizer Could Launch Three Significant NMEs in 2004; Will Any Surpass Viagra?
Pfizer's product outlook is brightening in 2004, with the launch of three commercially significant new molecular entity products on the horizon